Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8+T cell mediated immunity against Trypanosoma cruzi

被引:13
|
作者
Gupta, Shivali [1 ]
Garg, Nisha Jain [1 ,2 ,3 ,4 ]
机构
[1] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
[2] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
[3] Univ Texas Med Branch, Fac Inst Human Infect & Immun, Ctr Trop Dis, Galveston, TX 77555 USA
[4] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA
基金
美国国家卫生研究院;
关键词
Chagas disease; Trypanosoma cruzi; DNA-prime/MVA-boost approach; Antigenic candidates; Effector B and T cell responses; VACCINIA VIRUS ANKARA; CHAGAS HEART-DISEASE; INFECTION; MICE; ACTIVATION; SAFETY; IMMUNOGENICITY; INDETERMINATE; CONSTRUCTION; PATHOGENESIS;
D O I
10.1016/j.vaccine.2012.10.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study, we have characterized the immune mechanisms elicited by antigenic candidates, TcG2 and TcG4, delivered by a DNA-prime/MVA-boost approach, and evaluated the host responses to Trypanosoma cruzi infection in C57BL/6 mice. Immunization of mice with antigenic candidates elicited antigen-specific, high-avidity, trypanolytic antibody response (IgG2b > IgG1) and CD8(+)T cells that exhibited type-1 cytolytic effector (CD8(+)CD107a(+)IFN-gamma(+)Perforin(+)) phenotype. The extent of TcG2-dependent type 1 B and T cell immunity was higher than that noted in TcG4-immunized mice, and expanded accordingly in response to challenge infection with T. cruzi. The progression of chronic phase in immunized mice was associated with persistence of IgGs, 55-90% reduction in the frequency of proinflammatory (IFN-gamma(+) or TNF-alpha(+)) CD8(+)T cells, and an increase or emergence of immunoregulatory (IL-10(+)) CD4/CD8 T cells. The tissue parasitism, infiltration of inflammatory infiltrate, parasite persistence, and fibrosis were decreased by 82-92% in heart and skeletal muscle of immunized/chronically infected mice. Control mice exhibited a significantly low antibody response, consistent activation of effector CD8(+)T cells dominated by pro-inflammatory phenotype and mixed cytokine profile (IFN-gamma+TNF-alpha>IL-4+IL-10), parasite persistence and pathologic damage in chagasic hearts. We conclude that delivery of TcG2 or TcG4 by DNA-rMVA approach elicits effective antibody and CD8(+)T cell mediated immunity against T. cruzi and Chagas disease. The emergence of type 2 cytokine and T cell response in chronic phase was indicative of prevention of clinical disease. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7179 / 7186
页数:8
相关论文
共 43 条
  • [31] Vaccination with TAT-Antigen Fusion Protein Induces Protective, CD8+ T Cell-Mediated Immunity Against Leishmania Major
    Kronenberg, Katharina
    Brosch, Sven
    Butsch, Florian
    Tada, Yayoi
    Shibagaki, Naotaka
    Udey, Mark C.
    von Stebut, Esther
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (11) : 2602 - 2610
  • [32] Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell-Mediated Protective Immunity and Vaccination against Enteric Bacteria
    Sztein, Marcelo B.
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2018, 10 (09):
  • [33] Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8+ T Cell Response That Confers Partial Protection Against Infection With Trypanosoma cruzi
    Biscari, Lucia
    Kaufman, Cintia Daniela
    Farre, Cecilia
    Huhn, Victoria
    Florencia Pacini, Maria
    Bulfoni Balbi, Camila
    Andrea Gomez, Karina
    Perez, Ana Rosa
    Alloatti, Andres
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [34] CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+ T Cell Responses
    Kanuma, Tomohiro
    Yamamoto, Takuya
    Kobiyama, Kouji
    Moriishi, Eiko
    Masuta, Yuji
    Kusakabe, Takato
    Ozasa, Koji
    Kuroda, Etsushi
    Jounai, Nao
    Ishii, Ken J.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (12) : 4707 - 4715
  • [35] Trypanosoma cruzi-elicited CD8+ T cell-mediated myocarditis:: Chemokine receptors and adhesion molecules as potential therapeutic targets to control chronic inflammation?
    Lannes-Vieira, J
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2003, 98 (03): : 299 - 304
  • [36] Essential role of VLA-4/VCAM-1 pathway in the establishment of CD8+ T-cell-mediated Trypanosoma cruzi-elicited meningoencephalitis
    Roffê, E
    Silva, AA
    Marino, APMP
    dos Santos, PVA
    Lannes-Vieira, J
    JOURNAL OF NEUROIMMUNOLOGY, 2003, 142 (1-2) : 17 - 30
  • [37] Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+T cells against Aspergillus fumigatus infection
    Sun, Z.
    Zhu, P.
    Li, L.
    Wan, Z.
    Zhao, Z.
    Li, R.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (11) : 3089 - 3096
  • [38] Co-delivery of STING and TLR7/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+T cell-mediated melanoma remission
    Schunke, Jenny
    Hueppe, Natkritta
    Mangazeev, Nicole
    Speth, Kai R.
    Rohde, Katja
    Scho, Felicia
    Bolduan, Vanessa
    Schneider, Paul
    Klaus, Tanja
    Kuske, Michael
    Grabbe, Stephan
    Landfester, Katharina
    Mailander, Volker
    Fichter, Michael
    NANO TODAY, 2024, 57
  • [39] Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
    Utrilla-Trigo, Sergio
    Jimenez-Cabello, Luis
    Alonso-Ravelo, Ruyman
    Calvo-Pinilla, Eva
    Marin-Lopez, Alejandro
    Moreno, Sandra
    Lorenzo, Gema
    Benavides, Julio
    Gilbert, Sarah
    Nogales, Aitor
    Ortego, Javier
    VACCINES, 2020, 8 (03) : 1 - 21
  • [40] Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells
    van der Wulp, Willemijn
    Remst, Dennis F. G.
    Kester, Michel G. D.
    Hagedoorn, Renate S.
    Parren, Paul W. H. I.
    van Kasteren, Sander I.
    Schuurman, Janine
    Hoeben, Rob C.
    Ressing, Maaike E.
    Bleijlevens, Boris
    Heemskerk, Mirjam H. M.
    CANCER GENE THERAPY, 2024, 31 (01) : 58 - 68